Aclaris Therapeutics (ACRS) News Today $2.05 -0.13 (-5.96%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Aclaris Therapeutics (NASDAQ:ACRS) Stock Rating Upgraded by StockNews.comStockNews.com upgraded shares of Aclaris Therapeutics from a "sell" rating to a "hold" rating in a research report on Friday.November 15 at 3:15 AM | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 73.4% in OctoberNovember 15 at 2:25 AM | americanbankingnews.comNews Flash: Analysts Just Made A Meaningful Upgrade To Their Aclaris Therapeutics, Inc. (NASDAQ:ACRS) ForecastsNovember 13, 2024 | finance.yahoo.comFY2024 Earnings Forecast for ACRS Issued By Leerink PartnrsNovember 13, 2024 | americanbankingnews.comShort Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Grows By 73.4%Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) saw a large increase in short interest during the month of October. As of October 31st, there was short interest totalling 2,410,000 shares, an increase of 73.4% from the October 15th total of 1,390,000 shares. Based on an average daily volume of 525,700 shares, the days-to-cover ratio is currently 4.6 days.November 13, 2024 | marketbeat.comBML Capital Management LLC Buys 1,261,866 Shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS)BML Capital Management LLC raised its position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 9.7% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,250,000 shares of the biotechnology compNovember 12, 2024 | marketbeat.comEquities Analysts Set Expectations for ACRS FY2024 EarningsAclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Research analysts at Leerink Partnrs dropped their FY2024 earnings per share (EPS) estimates for Aclaris Therapeutics in a report issued on Thursday, November 7th. Leerink Partnrs analyst T. Smith now anticipates that the biotechnology compNovember 11, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Rating Lowered to Sell at StockNews.comNovember 9, 2024 | americanbankingnews.comStifel Nicolaus Sticks to Its Hold Rating for Aclaris Therapeutics (ACRS)November 8, 2024 | markets.businessinsider.comAclaris Therapeutics Reports Positive Q3 2024 MilestonesNovember 7, 2024 | markets.businessinsider.comAclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate UpdateNovember 6, 2024 | markets.businessinsider.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives Average Rating of "Hold" from BrokeragesShares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have earned an average recommendation of "Hold" from the six ratings firms that are currently covering the firm, MarketBeat Ratings reports. Six analysts have rated the stock with a hold rating. The average twelve-month target prOctober 30, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Sees Large Decline in Short InterestAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) saw a large drop in short interest during the month of October. As of October 15th, there was short interest totalling 1,390,000 shares, a drop of 19.7% from the September 30th total of 1,730,000 shares. Based on an average daily trading volume, of 339,700 shares, the days-to-cover ratio is presently 4.1 days.October 28, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Shares Pass Above 50 Day Moving Average - Time to Sell?Aclaris Therapeutics (NASDAQ:ACRS) Share Price Passes Above 50-Day Moving Average - Here's WhyOctober 26, 2024 | marketbeat.comAclaris Therapeutics, Inc. (ACRS)October 23, 2024 | finance.yahoo.comMillennium Management LLC Reduces Stake in Aclaris Therapeutics IncOctober 9, 2024 | finance.yahoo.comAclaris Therapeutics (NASDAQ:ACRS) Stock, Short Interest ReportOctober 7, 2024 | benzinga.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Shares Sold by Renaissance Technologies LLCRenaissance Technologies LLC trimmed its holdings in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 44.9% during the second quarter, according to its most recent Form 13F filing with the SEC. The firm owned 922,200 shares of the biotechnology company's stock after selling 751,2October 7, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Hold" by AnalystsShares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been given a consensus recommendation of "Hold" by the six brokerages that are currently covering the stock, Marketbeat reports. Six analysts have rated the stock with a hold rating. The average 1-year price target among broOctober 5, 2024 | marketbeat.comStonepine Capital Management LLC Purchases New Stake in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)Stonepine Capital Management LLC acquired a new position in shares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,927,4October 1, 2024 | marketbeat.comAclaris Therapeutics (ACRS) Gets a Hold from H.C. WainwrightSeptember 18, 2024 | markets.businessinsider.comHC Wainwright Reiterates Neutral Rating for Aclaris Therapeutics (NASDAQ:ACRS)HC Wainwright reissued a "neutral" rating on shares of Aclaris Therapeutics in a report on Tuesday.September 17, 2024 | marketbeat.comAclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to Severe Atopic DermatitisSeptember 17, 2024 | globenewswire.comAclaris Therapeutics Engages in 2024 Cantor Global Healthcare ConferenceSeptember 12, 2024 | msn.comAclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare ConferenceSeptember 10, 2024 | globenewswire.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Rating of "Hold" by AnalystsShares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been assigned a consensus rating of "Hold" from the seven brokerages that are covering the company, MarketBeat.com reports. Six analysts have rated the stock with a hold rating and one has issued a buy rating on the companSeptember 10, 2024 | marketbeat.com1,892,050 Shares in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Purchased by Trium Capital LLPTrium Capital LLP purchased a new position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 1,892,050 shares of the biotechnologSeptember 9, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Shares Pass Below 50 Day Moving Average of $1.24Aclaris Therapeutics (NASDAQ:ACRS) Share Price Crosses Below Fifty Day Moving Average of $1.24September 6, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Shares Cross Below 50 Day Moving Average of $1.24Aclaris Therapeutics (NASDAQ:ACRS) Stock Price Crosses Below Fifty Day Moving Average of $1.24August 29, 2024 | marketbeat.comAclaris Therapeutics, Inc. to Post FY2024 Earnings of ($0.66) Per Share, HC Wainwright Forecasts (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Equities research analysts at HC Wainwright increased their FY2024 earnings per share (EPS) estimates for shares of Aclaris Therapeutics in a research note issued to investors on Monday, August 19th. HC Wainwright analyst R. Selvaraju now aAugust 21, 2024 | marketbeat.comH.C. Wainwright Reaffirms Their Hold Rating on Aclaris Therapeutics (ACRS)August 20, 2024 | markets.businessinsider.comACRS Sep 2024 3.000 put (ACRS240920P00003000)August 18, 2024 | finance.yahoo.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Recommendation of "Hold" by AnalystsShares of Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) have been assigned an average rating of "Hold" from the seven research firms that are covering the company, Marketbeat reports. Six research analysts have rated the stock with a hold recommendation and one has issued a buy recomAugust 16, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Reported Earnings Last Week And Analysts Are Already Upgrading Their EstimatesAugust 10, 2024 | finance.yahoo.comAclaris Therapeutics: Hold Rating Amidst Clinical Uncertainty and Strategic ReviewAugust 9, 2024 | markets.businessinsider.comAclaris Therapeutics Reports Q2 2024 Financial Results and UpdatesAugust 9, 2024 | msn.comAclaris Therapeutics (NASDAQ:ACRS) Announces Earnings ResultsAclaris Therapeutics (NASDAQ:ACRS - Get Free Report) posted its quarterly earnings data on Wednesday. The biotechnology company reported ($0.15) EPS for the quarter, beating the consensus estimate of ($0.19) by $0.04. Aclaris Therapeutics had a negative return on equity of 61.03% and a negative net margin of 248.28%. The business had revenue of $2.77 million for the quarter, compared to the consensus estimate of $1.74 million.August 8, 2024 | marketbeat.comAclaris Therapeutics Reports Second Quarter 2024 Financial Results and Provides a Corporate UpdateAugust 7, 2024 | markets.businessinsider.comWill Aclaris Therapeutics (NASDAQ:ACRS) Spend Its Cash Wisely?August 6, 2024 | finance.yahoo.comInsider Buying: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Acquires 173,730 Shares of StockAugust 1, 2024 | insidertrades.comAclaris Therapeutics, Inc. (0H8T.L)July 30, 2024 | uk.finance.yahoo.comAclaris Therapeutics, Inc. to Post Q3 2024 Earnings of ($0.14) Per Share, HC Wainwright Forecasts (NASDAQ:ACRS)Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) - Stock analysts at HC Wainwright upped their Q3 2024 earnings per share estimates for Aclaris Therapeutics in a report issued on Monday, July 22nd. HC Wainwright analyst R. Selvaraju now expects that the biotechnology company will earn ($0.1July 24, 2024 | marketbeat.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Acquires $23,562.28 in StockJuly 23, 2024 | insidertrades.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Major Shareholder Purchases $23,562.28 in StockAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) major shareholder Braden Michael Leonard acquired 17,716 shares of the company's stock in a transaction dated Monday, July 22nd. The shares were bought at an average cost of $1.33 per share, for a total transaction of $23,562.28. Following the completion of the acquisition, the insider now directly owns 13,602,691 shares of the company's stock, valued at $18,091,579.03. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.July 22, 2024 | marketbeat.comH.C. Wainwright Keeps Their Hold Rating on Aclaris Therapeutics (ACRS)July 22, 2024 | markets.businessinsider.comAclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Average Rating of "Hold" by BrokeragesAclaris Therapeutics, Inc. (NASDAQ:ACRS - Get Free Report) has been given an average recommendation of "Hold" by the seven analysts that are covering the stock, MarketBeat.com reports. Six equities research analysts have rated the stock with a hold rating and one has given a buy rating to the comJuly 22, 2024 | marketbeat.comAclaris Therapeutics (NASDAQ:ACRS) Rating Reiterated by HC WainwrightHC Wainwright restated a "neutral" rating on shares of Aclaris Therapeutics in a research note on Monday.July 22, 2024 | marketbeat.comAclaris Therapeutics Announces Sale of OLUMIANT® Royalties and Milestones to OMERS Life Sciences for Up to $31.5 MillionJuly 16, 2024 | globenewswire.comGSA Capital Partners LLP Has $842,000 Stock Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS)GSA Capital Partners LLP lessened its holdings in Aclaris Therapeutics, Inc. (NASDAQ:ACRS - Free Report) by 57.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 679,137 shares of the biotechnology company's stock aJuly 12, 2024 | marketbeat.com3 Beaten Down Pharmaceuticals With Catalysts for Higher PricesTrading volume spikes in beaten-down stocks often signal a bottom for prices investors can bank on. The problem is that beaten-down stocks are usually in that position for a good reason, so it helps if there is a catalyst for higher share prices in addition to the trading volume.July 11, 2024 | marketbeat.com Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Why buying gold might be a mistake (Ad)Something strange just happened with gold. With the recent Fed rate cut… My charts are showing a breakout signal I haven't seen in years. But for now, I'm not rushing to buy gold. In fact, I'm telling everyone I know to hold off. Because I believe there’s a far better way to play this upcoming surge. It's a method that could turn a 1% gold price change into gains like 59%, 118%, or even 228%. And it doesn't involve buying a single ounce of physical gold or even buying any regular gold stock. I've been trading gold for nearly 20 years now and this is my #1 recommended approach for trading gold right now. Most traders miss them completely… But for those who know how to spot them, it takes their trades to a whole new level. If you're interested, check out the recording here while the link's still up. ACRS Media Mentions By Week ACRS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ACRS News Sentiment▼0.370.56▲Average Medical News Sentiment ACRS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ACRS Articles This Week▼122▲ACRS Articles Average Week Get Aclaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ACRS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Exscientia News Today Humacyte News Today CorMedix News Today Korro Bio News Today Acelyrin News Today Corvus Pharmaceuticals News Today Nuvation Bio News Today Q32 Bio News Today Mereo BioPharma Group News Today Monte Rosa Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ACRS) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aclaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aclaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
